Published in J Steroid Biochem Mol Biol on October 18, 2006
p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A (2009) 5.05
MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A (2010) 2.21
Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy (2011) 1.81
ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci U S A (2007) 1.37
Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One (2009) 1.25
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther (2010) 1.11
Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today (2012) 1.05
MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Mol Cancer (2014) 0.91
Effect of Qi-protecting powder (Huqi San) on expression of c-jun, c-fos and c-myc in diethylnitrosamine-mediated hepatocarcinogenesis. World J Gastroenterol (2007) 0.87
Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells. J Steroid Biochem Mol Biol (2015) 0.82
Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers. Breast Cancer Res Treat (2013) 0.82
The soy isoflavone equol may increase cancer malignancy via up-regulation of eukaryotic protein synthesis initiation factor eIF4G. J Biol Chem (2012) 0.81
Molecular characterizations of Nop16 in murine mammary tumors with varying levels of c-Myc. Transgenic Res (2011) 0.78
MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Br J Cancer (2016) 0.77
Activation of apoptosis in hepatocellular carcinoma by the Chinese traditional medicine Hu Qisan. Exp Ther Med (2012) 0.77
Stable inhibition of specific estrogen receptor α (ERα) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells. Endocrinology (2012) 0.77
Astrocyte elevated gene-1 promotes the proliferation and invasion of breast cancer cells by activating the Wnt/β-catenin signaling pathway. Oncol Lett (2017) 0.75
MYC-Driven Pathways in Breast Cancer Subtypes. Biomolecules (2017) 0.75
Expression of Rab5a correlates with tumor progression in pancreatic carcinoma. Virchows Arch (2017) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Cyclin D as a therapeutic target in cancer. Nat Rev Cancer (2011) 5.76
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements. Nucleic Acids Res (2007) 2.80
Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology (2008) 2.70
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A (2010) 2.67
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology (2007) 2.36
Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A (2003) 2.31
Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology (2003) 2.28
Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One (2007) 2.26
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol (2013) 2.26
Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol (2009) 2.21
Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat (2003) 2.14
The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev (2008) 2.13
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res (2009) 1.98
Prostate specific antigen testing: age-related interpretation in early prostate cancer detection. Pathology (2013) 1.98
Improved glucose homeostasis and enhanced insulin signalling in Grb14-deficient mice. EMBO J (2004) 1.97
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 1.95
Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol (2009) 1.94
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology (2009) 1.91
Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell (2012) 1.91
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer (2010) 1.89
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res (2003) 1.81
Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology (2008) 1.81
DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol (2002) 1.78
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer (2005) 1.73
Cyclins and breast cancer. J Mammary Gland Biol Neoplasia (2004) 1.73
Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. J Clin Invest (2010) 1.70
Cell cycle control in breast cancer cells. J Cell Biochem (2006) 1.68
Socs2 and elf5 mediate prolactin-induced mammary gland development. Mol Endocrinol (2006) 1.65
Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res (2004) 1.65
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res (2010) 1.62
Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas. J Gastroenterol Hepatol (2011) 1.60
Molecular evolutionary relationships of enteroinvasive Escherichia coli and Shigella spp. Infect Immun (2004) 1.59
Outcomes of transperineal template-guided prostate biopsy in 409 patients. BJU Int (2013) 1.55
EphB4 expression and biological significance in prostate cancer. Cancer Res (2005) 1.53
Molecular markers of prostate cancer outcome. Eur J Cancer (2005) 1.52
Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation. EMBO J (2005) 1.52
An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res (2005) 1.52
Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res (2005) 1.48
Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer (2003) 1.47
Galanin mediates the pathogenesis of cerulein-induced acute pancreatitis in the mouse. Pancreas (2010) 1.43
Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res (2003) 1.43
Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One (2008) 1.42
Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proc Natl Acad Sci U S A (2005) 1.41
Clinically relevant prognostic markers for prostate cancer: the search goes on. Ann Intern Med (2009) 1.38
Y4 receptor knockout rescues fertility in ob/ob mice. Genes Dev (2002) 1.38
Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development. Mol Endocrinol (2002) 1.37
The E3 ubiquitin ligase EDD regulates S-phase and G(2)/M DNA damage checkpoints. Cell Cycle (2007) 1.36
The alveolar switch: coordinating the proliferative cues and cell fate decisions that drive the formation of lobuloalveoli from ductal epithelium. Breast Cancer Res (2006) 1.35
EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response. J Biol Chem (2002) 1.34
Therapeutic targets in triple negative breast cancer. J Clin Pathol (2013) 1.33
Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol (2009) 1.32